C Woodhouse1, T Ward2, M Gaskill-Shipley3, R Chaudhary2. 1. University of Cincinnati Medical Center, Cincinnati, OH, U.S.A. 2. Division of Hematology/Oncology, Department of Medicine, University of Cincinnati Medical Center, Cincinnati, OH, U.S.A. 3. Department of Radiology, University of Cincinnati Medical Center, Cincinnati, OH, U.S.A.
Abstract
Background: Gliomas are the most dreaded primary brain tumour because of their dismal cure rates. Ketogenic-type diets (kds) are high-fat, low-protein, and low-carbohydrate diets; the modified Atkins diet (mad) is a less-stringent version of a kd that still generates serum ketones in patients. The purpose of the present study was to retrospectively examine the feasibility of attaining ketosis and the safety of the mad in patients undergoing radiation and chemotherapy treatment for glioma. The rate of pseudoprogression (psp) after treatment was also assessed as a marker of radiation sensitization. To our knowledge, this dataset is the largest published relating to patients with glioma undergoing kd during radiation and chemotherapy. Methods: We retrospectively studied 29 patients with grades ii-iv astrocytoma following the mad during standard radiation and chemotherapy. Feasibility of attaining ketosis was assessed though levels of beta hydroxybutyrate in blood. Pre- and post-radiation magnetic resonance images were evaluated for psp by a neuroradiologist blinded to patient data. Results: In the 29 patients who started the mad during radiation, ketosis was achieved in all 29 (100%). No serious adverse events occurred secondary to the mad. Of those 29 patients, 19 had glioblastoma multiforme. Of the latter 19 patients, 11 (58%) showed psp after mad and radiation and temozolomide therapy. Conclusions: A modified Atkins diet is feasible and safe for glioma patients during radiation and chemotherapy treatment. The mad and resulting ketosis could play a role as a radiation sensitizer.
Background: Gliomas are the most dreaded primary brain tumour because of their dismal cure rates. Ketogenic-type diets (kds) are high-fat, low-protein, and low-carbohydrate diets; the modified Atkins diet (mad) is a less-stringent version of a kd that still generates serum ketones in patients. The purpose of the present study was to retrospectively examine the feasibility of attaining ketosis and the safety of the mad in patients undergoing radiation and chemotherapy treatment for glioma. The rate of pseudoprogression (psp) after treatment was also assessed as a marker of radiation sensitization. To our knowledge, this dataset is the largest published relating to patients with glioma undergoing kd during radiation and chemotherapy. Methods: We retrospectively studied 29 patients with grades ii-iv astrocytoma following the mad during standard radiation and chemotherapy. Feasibility of attaining ketosis was assessed though levels of beta hydroxybutyrate in blood. Pre- and post-radiation magnetic resonance images were evaluated for psp by a neuroradiologist blinded to patient data. Results: In the 29 patients who started the mad during radiation, ketosis was achieved in all 29 (100%). No serious adverse events occurred secondary to the mad. Of those 29 patients, 19 had glioblastoma multiforme. Of the latter 19 patients, 11 (58%) showed psp after mad and radiation and temozolomide therapy. Conclusions: A modified Atkins diet is feasible and safe for gliomapatients during radiation and chemotherapy treatment. The mad and resulting ketosis could play a role as a radiation sensitizer.
Authors: Colin E Champ; Joshua D Palmer; Jeff S Volek; Maria Werner-Wasik; David W Andrews; James J Evans; Jon Glass; Lyndon Kim; Wenyin Shi Journal: J Neurooncol Date: 2014-01-19 Impact factor: 4.130
Authors: Jeffrey C Rathmell; Casey J Fox; David R Plas; Peter S Hammerman; Ryan M Cinalli; Craig B Thompson Journal: Mol Cell Biol Date: 2003-10 Impact factor: 4.272
Authors: Monika E Hegi; Annie-Claire Diserens; Thierry Gorlia; Marie-France Hamou; Nicolas de Tribolet; Michael Weller; Johan M Kros; Johannes A Hainfellner; Warren Mason; Luigi Mariani; Jacoline E C Bromberg; Peter Hau; René O Mirimanoff; J Gregory Cairncross; Robert C Janzer; Roger Stupp Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245
Authors: Gabriele D Maurer; Daniel P Brucker; Oliver Bähr; Patrick N Harter; Elke Hattingen; Stefan Walenta; Wolfgang Mueller-Klieser; Joachim P Steinbach; Johannes Rieger Journal: BMC Cancer Date: 2011-07-26 Impact factor: 4.430
Authors: Eun Jung Choi; Bong Jun Cho; David J Lee; Yeo Hyeon Hwang; Sun Ha Chun; Hans H Kim; In Ah Kim Journal: BMC Cancer Date: 2014-01-13 Impact factor: 4.430
Authors: Mohammed G Abdelwahab; Kathryn E Fenton; Mark C Preul; Jong M Rho; Andrew Lynch; Phillip Stafford; Adrienne C Scheck Journal: PLoS One Date: 2012-05-01 Impact factor: 3.240
Authors: Joachim P Steinbach; Claus Rödel; Johannes Rieger; Martin Voss; Katharina J Wenger; Nina von Mettenheim; Jörg Bojunga; Manuela Vetter; Bianca Diehl; Kea Franz; Ruediger Gerlach; Michael W Ronellenfitsch; Patrick N Harter; Elke Hattingen Journal: Eur J Nutr Date: 2021-09-06 Impact factor: 5.614
Authors: Kenneth A Schwartz; Mary Noel; Michele Nikolai; Lawrence K Olson; Norman G Hord; Micheal Zakem; Justin Clark; Mohamed Elnabtity; Bryan Figueroa; Howard T Chang Journal: Front Nutr Date: 2022-05-03